EGFR and non-small cell lung carcinoma: Mutations in T790M and C797 within the ATP receptor cause NSCLC to be resistant to EGFR-TKIs, and it has been found that the EAI045 inhibitor works by targeting such mutants and has good efficacy in combination with cetuximab for the treatment of EGFR-TKIs resistant mutants in LC (179).